Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Arcus Biosciences (NYSE:RCUS) has granted equity awards to four new employees through its 2020 Inducement Plan. The grants include options to purchase 66,900 shares of common stock at an exercise price of $15.96 per share, which matched the closing price on December 23, 2024. Additionally, the employees received restricted stock units to acquire 33,450 shares of common stock. These awards were approved by the Compensation Committee under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS) ha concesso premi azionari a quattro nuovi dipendenti attraverso il suo Piano di Induzione 2020. I premi includono opzioni per acquistare 66.900 azioni di azioni ordinarie a un prezzo di esercizio di 15,96 dollari per azione, che corrisponde al prezzo di chiusura del 23 dicembre 2024. Inoltre, i dipendenti hanno ricevuto unità azionarie soggette a restrizioni per acquisire 33.450 azioni di azioni ordinarie. Questi premi sono stati approvati dal Comitato di Compensazione ai sensi dell’eccezione del Regolamento 303A.08 del Manuale delle Aziende Quotate della NYSE.
Arcus Biosciences (NYSE:RCUS) ha otorgado premios de acciones a cuatro nuevos empleados a través de su Plan de Inducción 2020. Los premios incluyen opciones para comprar 66,900 acciones de acciones ordinarias a un precio de ejercicio de $15.96 por acción, que coincide con el precio de cierre del 23 de diciembre de 2024. Además, los empleados recibieron unidades de acciones restringidas para adquirir 33,450 acciones de acciones ordinarias. Estos premios fueron aprobados por el Comité de Compensación bajo la excepción de inducción de la Regla 303A.08 del Manual de Empresas Listadas de la NYSE.
Arcus Biosciences (NYSE:RCUS)는 2020 유도 계획을 통해 네 명의 신입 직원에게 주식 보상을 부여했습니다. 이 보상에는 66,900주의 일반주식을 주당 $15.96에 구매할 수 있는 옵션이 포함되어 있으며, 이는 2024년 12월 23일의 종가와 일치합니다. 또한 직원들은 33,450주의 일반주식을 확보할 수 있는 제한 주식 단위도 받았습니다. 이 보상은 NYSE 상장회사 매뉴얼 규칙 303A.08의 유도 예외에 따라 보상위원회에서 승인되었습니다.
Arcus Biosciences (NYSE:RCUS) a accordé des attributions d’actions à quatre nouveaux employés dans le cadre de son Plan d’Induction 2020. Les attributions incluent des options d’achat de 66.900 actions ordinaires à un prix d’exercice de 15,96 $ par action, ce qui correspond au prix de clôture du 23 décembre 2024. De plus, les employés ont reçu des unités d’actions restreintes pour acquérir 33.450 actions ordinaires. Ces attributions ont été approuvées par le Comité de Rémunération conformément à l’exception d’induction de la règle 303A.08 du Manuel des Sociétés Cotées de la NYSE.
Arcus Biosciences (NYSE:RCUS) hat vier neuen Mitarbeitern durch seinen Induktionsplan 2020 Aktienvergütungen gewährt. Die Vergaben umfassen Optionen zum Kauf von 66.900 Aktien ohne Nennwert zu einem Ausübungspreis von 15,96 $ pro Aktie, was dem Schlusskurs am 23. Dezember 2024 entspricht. Darüber hinaus erhielten die Mitarbeiter eingeschränkte Aktieneinheiten, um 33.450 Aktien zu erwerben. Diese Auszeichnungen wurden vom Vergütungsausschuss gemäß der Ausnahmeregelung 303A.08 des Handbuchs für notierte Unternehmen der NYSE genehmigt.
Positive
- Stock-based compensation helps attract and retain talent without immediate cash expenditure
Negative
- Potential future dilution for existing shareholders from 100,350 total new shares
- Additional stock-based compensation expense will impact financial statements
HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 66,900 shares of the Company’s common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024, and restricted stock units to acquire a total of 33,450 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20241224871937/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
Source: Arcus Biosciences
FAQ
How many shares were granted in Arcus Biosciences (RCUS) December 2024 inducement awards?
Arcus Biosciences granted options for 66,900 shares and restricted stock units for 33,450 shares, totaling 100,350 shares.
What was the exercise price for RCUS stock options granted on December 23, 2024?
The exercise price for the stock options was $15.96 per share, matching the closing price on December 23, 2024.
How many employees received RCUS inducement grants in December 2024?
Four new employees received inducement grants from Arcus Biosciences.
Under which plan were the RCUS equity awards granted in December 2024?
The equity awards were granted under Arcus Biosciences’ 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08.
